You are here

Matsusaka Satoshi

Researcher's full information

Refereed academic journal/Refereed international conference paper
  • A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsu...
    Gastric Cancer./20(2)/pp.350-357, 2017-03
  • Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer.
    Y Sunakawa; S Cao; MD Berger; S Matsusaka; D Yang; Zhang ...
    Pharmacogenomics J/17(1)/pp.36-41, 2017-01
  • Genetic variants associated with colorectal brain metastases susceptibility and survival.
    Stremitzer S; Berghoff AS; Volz NB; Zhang W; Yang D; Stin...
    Pharmacogenomics J./17(1)/pp.29-35, 2017-01
  • Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab
    S Okazaki; F Loupakis; S Stintzing; S Cao; W Zhang; D Yan...
    Mol Cancer Ther/15(7)/pp.1740-1745, 2016
  • Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy
    S Matsusaka; T Kobunai; N Yamamoto; K Chin; M Ogura; G Ta...
    Genes Cancer/7(1-2)/pp.27-35, 2016
  • Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
    Matsusaka Satoshi; A Nashimoto; K Nishikawa; A Miki; H Mi...
    Gastric Cancer/19(3)/pp.839-851, 2016
  • Letter in response to "Our HER2 is same as yours"
    松阪 諭; Yoshida K
    Transl Gastroenterol Hepatol/1/pp.18-18, 2016
  • Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
    S Stremitzer; W Zhang; D Yang; Y Ning; Y Sunakawa; S Mats...
    Mol Cancer Ther/15(11)/pp.2814-2821, 2016
  • Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012
    MD Berger; D Yang; Y Sunakawa; W Zhang; Y Ning; S Matsusa...
    Oncotarget/7(33)/pp.53668-53678, 2016
  • TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
    Matsusaka S; Zhang W; Cao S; Hanna DL; Sunakawa Y; Sebio ...
    Mol Cancer Ther/15(6)/pp.1405-1411, 2016
  • Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
    M Suenaga; T Mashima; N Kawata; T Wakatsuki; Y Horiike; S...
    Oncotarget/7(23)/pp.34811-34823, 2016
  • RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy
    H Osumi; E Shinozaki; M Suenaga; S Matsusaka; T Konishi; ...
    Int J Cancer/139(4)/pp.803-811, 2016
  • Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy
    Matsusaka Satoshi; DL Hanna; S Cao; W Zhang; D Yang; Y Ni...
    Clin Cancer Res/22(13)/pp.3218-3126, 2016
  • Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
    H Osumi; T Yoshio; K Chin; M Ogura; Y Kumekawa; M Suenaga...
    Gastric Cancer./19(2)/pp.625-630, 2016
  • Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
    Matsusaka Satoshi; S Matsusaka; W Zhang; D Yang; Y Ning; ...
    Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer./16(4)/pp.312-319, 2016
  • Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
    H Osumi; E Shinozaki; M Osako; Y Kawazoe; M Oba; T Misaka...
    Mol Clin Oncol./3(5)/pp.1053-1057, 2015
  • Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients.
    Y Sato; S Matsusaka; M Suenaga; E Shinozaki; N. Mizunuma
    Onco Targets Ther./8/pp.3329-3336, 2015
  • Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients.
    Matsusaka Satoshi; S Matsusaka; T Wakatsuki; M Suenaga; E...
    Mol Clin Oncol./3(6)/pp.1295-1300, 2015
  • Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
    M Suenaga; N Mizunuma; S Matsusaka; E Shinozaki; M Ozaka;...
    Drug Des Devel Ther/9/pp.3099-3108, 2015
  • Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
    Stintzing S; Zhang W; Heinemann V; Neureiter D; Kemmerlin...
    Mol Cancer Ther/14(10)/pp.2374-2381, 2015
  • Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.
    Y Ning; DL Hanna; W Zhang; A Mendez; D Yang; R El-Khoueir...
    Mol Cancer Ther/14(10)/pp.2401-2408, 2015
  • Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
    H Osumi; E Shinozaki; M Suenaga; Y Kumekawa; M Ogura; M O...
    BMC Cancer/15/pp.760-760, 2015
  • Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
    Matsusaka Satoshi
    Ann Oncol./26(12)/pp.2450-2456, 2015
  • Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
    Y Sunakawa; S Stintzing; S Cao; V Heinemann; C Cremolini;...
    Ann Oncol./26(12)/pp.2450-2456, 2015
  • Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab.
    H Osumi; S Matsusaka; M Suenaga; E Shinozaki; N Mizunuma
    Onco Targets Ther./8/pp.2005-2013, 2015